Rapport Therapeutics, Inc. (RAPP)

Rapport Therapeutics Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022
Period Ending	Jun 30, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022
Cash & Equivalents	55.07	56.81	70.17	31.16
Short-Term Investments	205.38	248.48	77.31	-
Cash & Short-Term Investments	260.45	305.28	147.48	31.16
Cash Growth	-22.52%	107.00%	373.31%	-
Prepaid Expenses	9.69	0.3	1.5	0.11
Restricted Cash	0.11	0.11	0.09	-
Other Current Assets	-	4.12	1.81	-
Total Current Assets	270.24	309.8	150.87	31.27
Property, Plant & Equipment	14.22	4.97	4	0.34
Long-Term Deferred Charges	0.3	-	0.3	-
Other Long-Term Assets	0.73	0.16	0.25	-
Total Assets	285.5	314.93	155.42	31.6
Accounts Payable	3.18	1.95	2.5	1.45
Accrued Expenses	6.94	6.08	5.63	0.21
Current Portion of Leases	1.76	0.74	0.67	-
Total Current Liabilities	11.88	8.77	8.8	1.66
Long-Term Debt	-	-	4.2	10.44
Long-Term Leases	10.1	0.74	1.48	-
Total Liabilities	21.98	9.51	14.48	12.1
Common Stock	0.04	0.04	0	0.03
Additional Paid-In Capital	438.09	429.66	19.8	0.56
Retained Earnings	-174.54	-123.75	-45.44	-10.65
Comprehensive Income & Other	-0.08	-0.52	0	-
Total Common Equity	263.51	305.43	-25.63	-10.06
Shareholders' Equity	263.51	305.43	140.94	19.51
Total Liabilities & Equity	285.5	314.93	155.42	31.6
Total Debt	11.86	1.48	6.35	10.44
Net Cash (Debt)	248.58	303.8	141.13	20.72
Net Cash Growth	-25.64%	115.26%	581.01%	-
Net Cash Per Share	7.05	14.65	93.73	26.66
Filing Date Shares Outstanding	36.5	36.5	4.17	0.78
Total Common Shares Outstanding	36.5	36.58	4.17	0.78
Working Capital	258.36	301.04	142.07	29.61
Book Value Per Share	7.22	8.35	-6.15	-12.95
Tangible Book Value	263.51	305.43	-25.63	-10.06
Tangible Book Value Per Share	7.22	8.35	-6.15	-12.95
Machinery	4.35	3.78	1.76	0.3
Construction In Progress	-	0.43	0.03	0.06
Leasehold Improvements	0.28	0.28	0.26	-

Updated Aug 7, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q